Dossier
Sentara-EVMS Comprehensive Sickle Cell Program
Coverage of Sentara-EVMS Comprehensive Sickle Cell Program in the Nexus archive.
- Virginia budget expands Medicaid access to sickle cell gene therapy
Virginia lawmakers allocated $15 million over two years to expand Medicaid coverage for gene therapy treatments for sickle cell disease. The funding enables Virginia to separately pay for gene therapy drugs and associated care, improving access for Medicaid patients. Sentara-EVMS Comprehensive Sickle Cell Program serves over 200 adults in Hampton Roads, referring eligible patients to VCU Health for gene therapy, which involves a complex, months-long process including chemotherapy and cell infusion.